Lung Cancer Considered

In this episode, we will discuss the FDA approval of telisotuzumab vedotin, an antibody drug conjugate, for NSCLC with high c-MET expression. To help review the data and offer perspective on this new agent, I am joined by two expert thoracic oncologists. I want to welcome Dr. Mor Moskovitz, Head of the Thoracic Medical Oncology Service at Davidoff Cancer Center at the Rabin Medical Center in Petah Tikva, Israel.

LCC in Korean: Lung Cancer Updates & Future Directions by IASLC

Global Advances and Persistent Disparities in Lung Cancer Treatment by IASLC

Dr. Bryant Lin Teaching My Cancer by IASLC

AACR 2025 Highlights by IASLC

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion live from the Texas Lung Cancer Conference with Dr. Mihaela Aldea about the key information about RET-positive NSCLC, from diagnostic challenges to treatment selection. Join us in this lively discussion.

Live from Texas Lung - Patient Education by IASLC

Guest: Dr. Corey Langer is the Director of Thoracic Oncology and Professor of Medicine at the Hospital of the University of Pennsylvania

Virtual Tumor Board: Targeting Residual Disease by IASLC

LCC in Korean: 2024 Lung Cancer Updates by IASLC

The Microbiome and Immunotherapy for Lung Cancer by IASLC

Live from TTLC25: Brain Metastasis by IASLC

LCC in Mandarin: Virtual Tumor Board - EGFR NSCLC by IASLC

Host: Ece Cali Daylan, Assistant Professor of Medicine, Division of Oncology at Washington University School of Medicine Guest: Saadettin Kilickap Guest: Ozden Altundag

LCC in Italian: Virtual Tumor Board - Resectable NSCLC by IASLC

As part of IASLC's ongoing series of podcasts in world languages, Dr. Balazs Halmos moderates a discussion in Hungarian with Dr. Krisztina Bogos, Dr. Ferenc Rényi-Vámos and Dr. Zsolt Megyesfalvi. The podcast reviews recent advances in lung cancer screening, diagnosis and management with a particular focus on implementation in Hungary. Highlights of the discussion include novel staging and diagnostic tools, state-of-the-art biomarker testing, perioperative therapy and clinical trials access. Host: Balazs Halmos, MD, Director, Thoracic Oncology & Clinical Cancer Genomics, Montefiore Medical Park at Eastchester, Bronx, New York Guest: Ferenc Rényi-Vámos, MD, PhD, Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary Guest: Krisztina Bogos, MD, Thoracic Oncology National Koranyi Institute of Pulmonology, Budapest, Hungary Lung Cancer Research and Pathology Guest: Zsolt Megyesfalvi, MD, PhD, Semmelweis University and National Institute of Oncology, Budapest, Hungary and National Koranyi Institute of Pulmonology, Budapest, Hungary

The 2024 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC's 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Sally Lau moderates a discussion in Cantonese Chinese about highlights from the conference with Dr. David Lee and Dr. Molly Li.

Virtual Tumor Board: Stage III ALK+ NSCLC by IASLC

Live from TTLC25: Targeted Therapy in Early Stage NSCLC Debate by IASLC

In this episode of Lung Cancer Considered, host Dr. Narjust Florez engages in a discussion with patient advocate Summer Farmen. Listen to the episode to learn about Summer's journey through diagnosis and treatment, and the importance of patient advocate groups. • Summer Farmen ALKtALK Program Coordinator Board Member, ALK Positive, Inc.

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on how small cell lung cancer continues to evolve with new treatment options and recent FDA approval. Listen to the episode to learn about the current standard of care and future therapies with a brief discussion about small cell transformation. Guest: Triparna Sen, MD Associate Professor Director, Lung Cancer PDX Program, Icahn School of Medicine at Mount Sinai Guest: Jacob Sands, MD Assistant Professor of Medicine, Harvard Medical School Lowe Cancer Center for Thoracic Oncology Dana Farber Cancer Institute

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of two of the most challenging thoracic malignancies – NUT carcinoma and mesothelioma. Listen to the episode to learn about the role of next-generation sequencing in diagnosis and treatment selection, as well as current and future targeted therapy in the management of both. Guests Melina Marmarelis, MD MSCE Assistant Professor Medical Director, UPenn Mesothelioma University of Pennsylvania Jia Luo, MD Medical Oncologist, Thoracic Oncology Program, Dana-Farber Cancer Institute Faculty, Brigham and Women's Hospital and Harvard Medical School

Descriptions: As part of the IASLC's ongoing series of podcasts in world languages, Dr. Nagla Abdel Karim moderates a discussion in Arabic with Dr. Bashir Abu Aqeel and Dr. Fawzi Abu Rous. The group discusses chemoimmunotherapy in metastatic non-small cell lung cancer.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case involving drug resistance in EGFR mutant NSCLC. This discussion takes the listener through the treatment of EGFR mutant NSCLC after acquired resistance to osimertinib. Guest: Dr. Yasushi Goto from National Cancer Center, Japan in Tokyo Guest: Dr. Rachel Sanborn, the Earle A. Chiles Research Institute of the Providence Cancer Institute in Portland, Oregon

This episode of Lung Cancer Considered covers the recent FDA approval of Osimertinib after chemo-radiation in EGFR positive NSCLC based on the LAURA trial which was presented at the 2024 ASCO Annual Meeting. Host Dr. Narjust Florez goes in depth with podcast guest Dr. Pamela Samson about the LAURA Trial and its implications for patients and clinicians. Guest: Dr. Pamela Samson is an assistant professor in the Department of Radiation Oncology at Washington University in St. Louis. Dr. Samson specializes in the care of thoracic malignancies and ways to deliver appropriate radiation therapy without compromising efficacy and diminishing toxicities.

Description: As part of IASLC's commitment to communicating in all world languages, this episode of Lung Cancer Considered is recorded in German and is part of our Virtual Tumor Board series. Host Professor Alessandra Curioni-Fontecedro moderates a discussion with two colleagues, who will discuss the dynamic topic of managing resectable stage III NSCLC. Host: Prof Alessandra Curioni-Fontecedro, MD, Head of Oncology, Cantonal Hospital Fribourg, Chair of Medical Oncology, University of Fribourg Guest: Prof. Isabelle Opitz, Professor of Thoracic Surgery and Director of the Department of Thoracic Surgery at University Hospital of Zurich, Chair of the Lung Cancer Center of Zurich, and the past President of the European Society of Thoracic Surgery. She received the IASLC Robert J Ginsberg Lectureship Award for Surgery at the 2022 World Conference on Lung Cancer Guest: Prof. Michael Thomas, Chefarzt of Dept of Thoracic Oncology at the Thoraxklinik Heidelberg, Germany.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of zenocutuzumab for NSCLC with an NRG1 fusion. NRG1 fusions are rare but important events seen in many cancer types, including NSCLC. Zenocutuzumab is a HER2/HER3 bispecific antibody that showed clear efficacy in NSCLC and in pancreatic cancer that harbored an NRG1 fusion. Guest: Dr. Alison Schram, Assistant Attending Physician and Section Head of Oral Therapeutics in Early Drug Development at Memorial Sloan Kettering Cancer Center in New York

ESMO Immuno-Oncology Congress 2024 Highlights Description: In this episode of Lung Cancer Considered, host Dr. Narjust Florez and Dr. Alfredo Addeo discuss some of the data presented at The ESMO Immuno-Oncology Congress 2024, which took place in December 2024 in Geneva, Switzerland. Guest: Dr. Alfredo Addeo, Professor and Chief of Oncology, University Hospital of Geneva

En este episodio de Lung Cancer Considered, vamos a hablar sobre el cancer de pulmón en México. Tengo el placer de tener en este episodio dos doctores con mucha experiencia tratando y entendiendo las necesidades de los pacientes con cancer de pulmón en México. Este episodio es una introducción y esperamos tener conversaciones as profundas en el futuro. Bio: Tenemos al Dr. Jorge Alatorre, Oncology clínico con Alta especialidad en Tumores del Tórax (Cáncer de pulmón y Mesotelioma). Y es jefe del Servicio de Oncología Médica del Instituto Nacional de Enfermedades Respiratorias (INER). También ofrece consulta en el Centro Médico ABC Santa Fe y en ONCARE ubicados en la Ciudad de México Bio: Dr. Silviano Rios, Cirujano torácico de la ciudad de Monterrey en México. Atiende a sus pacientes en el Hospital Zambrano Hellion y TecSalud y se especializa en cirugía mínimamente invasiva.

Preview: 2025 Pan-Africa Lung Cancer Meeting The 2025 Pan-Africa Lung Cancer Conference will take place January 31 - February 1, 2025, in Accra, Ghana and represents the first IASLC multidisciplinary lung cancer conference in Sub-Saharan Africa. In this episode of Lung Cancer Considered, host Dr. Narjust Florez talks with the conference co-chairs about this groundbreaking meeting and what attendees will experience at the meeting. Guest: Dr. Chukwumere E. Nwogu is a Professor of Surgery at Roswell Park Cancer Institute and the University at Buffalo Jacobs School of Medicine & Biomedical Sciences Guest: Dr. Jane Sandra Afriyie-Mensah is a Senior Pulmonologist and a Distinguished Academic and Researcher, currently affiliated with the University of Ghana and Korle Bu Teaching Hospital. X: NA

Lung Cancer Considered host Dr. Stephen Liu and two distinguished thoracic oncologists review the highlights from the recently completed ESMO Asia 2024 meeting, held in Singapore. The episode covers a number of trials, including an update on FLAURA2, TROPION-Lung01 and TROPION-Lung05, ALESIA, and PACIFIC 5. Guest: Dr. Misako Nagasaka, Associate Professor from the University of California, Irvine Guest: by Dr. Molly Li, Clinical Assistant Professor from Chinese University of Hong Kong.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of perioperative nivolumab based on the Phase III CheckMate 77T study. Perioperative therapy has improved outcomes in patients with resectable NSCLC and is emerging as best practice but there is nuance to the delivery of this therapy. Guest: Dr. Tina Cascone is a Physician-Scientist and Associate Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas and lead author of the CheckMate 77T manuscript in the New England Journal of Medicine Guest: Dr. Shun Lu is the Chief of Shanghai Lung Cancer Center and Shanghai Chest Hospital and Professor at Shanghai Jiaotong University. He is an executive board member of the Chinese Society of Clinical Oncology and past chair of Chinese Lung Cancer Association

Tumor Treating Fields (TTFields) is a non-invasive cancer treatment that uses alternating electric fields to disrupt the ability of cancer cells to divide. TTFields can slow down tumor growth and spread, and may help people live longer than chemotherapy alone. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses this new therapy and the Phase III LUNAR study that led to its FDA approval. Guest: Dr. Ticiana Leal is an Associate Professor and serves as Director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine.

In this episode of Lung Cancer Considered host Dr. Narjust Florez discusses the future of lung cancer research in Brazil and the largest lung cancer screening program in South America. The episode was recorded during the IASLC 2024 Latin America Conference on Lung Cancer held in Bogota, Columbia. Guests: Clarissa Baldotto is a Medical ) Oncologist at D'Or Rio De Janeiro and President Elect for the Brazilian Society of Clinical Oncology (SBOC) Guest: Dr. Francisco Sarmento is a Thoracic Radiologist from Hospital Royal Portuguese in Brazil.

Lung Cancer Considered in German by IASLC

In this episode of Lung Cancer Considered, host Dr. Stephen Liu and guests preview the publication of the Ninth Edition of Tumor, Node and Metastasis (TNM) Classification System for lung cancer. The new edition will be published in January 2025 and has some important changes that reflect an evolving understanding of the disease and more rigorous analysis of data from around the world. Guest: Dr. Valerie Rusch is a Thoracic Surgeon from Memorial Sloan Kettering Cancer CenterMSKCC where she is Vice Chair for Clinical Research in the Department of Surgery and the Miner Family Chair in Intrathoracic Cancers. She has held many leadership positions in the American College of Surgeons and other organizations and was part of the team to first described EGFR mutations. She has been chair of the Thoracic Committee for the American Joint Committee on Cancer 6th, 7th, 8th, and now 9th Editions of the Cancer Staging Handbook Guest: Dr. Hisao Asamura is a Professor of Surgery, Chief of Division of Thoracic Surgery at Keio University School of Medicine in Tokyo, Japan and Vice President of the Japan Lung Cancer Society. For IASLC, he is the Chair of the Staging and Prognostic Factors Committee, former Executive Board Director, and Congress President for the 18th World Conference on Lung Cancer. Guest: Dr. Enrico Ruffini is a Thoracic Surgeon and Professor of Thoracic Surgery from the University of Torino, Italy where he is the Chief of the Thoracic Surgery Unit and Director of the Thoracic Surgery Residency Program. He is heavily involved in the European Society of Thoracic Surgeons and Chair of the IASLC Staging and Prognostic Factors Committee – Thymic domain.

Lung Cancer Considered host Dr. Narjust Florez and Dr. Suresh Ramalingam discuss the recent FDA approval of osimertinib after chemo-radiation in EGFR positive NSCLC. The approval was based, in part, on the results of the LAURA trial, which was presented at the 2024 ASCO Annual Meeting. Guest: Dr. Suresh Ramalingam is the Executive Director, Winship Cancer Institute of Emory University, the Roberto C. Goizueta Distinguished Chair for Cancer Research, and a professor of medicine at Emory University School of Medicine. He is also the editor in chief for the Cancer Journal.

Lung cancer breakthroughs, practice updates, and key meetings made 2024 one of the most consequential years in recent memory for lung cancer researchers and clinicians. Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu reviewed important meetings and significant clinical trials from 2024 in this special episode.

Description: Join us for an engaging discussion on groundbreaking research from investigators across Latin America, featuring insights from large lung cancer screening programs in Mexico and real-world data from the FLAURA-2 study. Titulo: Únete a nosotros para discutir nuevos datos e interesantes presentados por investigadores emergentes en América Latina, desde grandes programas de detección temprana de cáncer de pulmón en México hasta datos del mundo real de FLAURA-2. Guest: Dr. Sergio Mejia – Oncologo clínico de la Fundación Instituto de Cancerología en Bogota, Colombia presento Datos del mundo real usando FLAURA-2 Guest: Dr. Luis Leonardo Rojas – Jefe Unidad Funcional GU y Tórax, Fundación CTIC-Luis Carlos Sarmiento Angulo, Bogota Colombia presento sobre el beneficio económico de tener estudios clínicos en Colombia para los canceres mas comunes Guest: Dra. Marisol Arroyo, pulmonologa del instituto de cancerología en la ciudad de Mexico. Discutió con nosotros los programas de detección temprana para el cancer de pulmón en Mexico

Description: In this virtual tumor board episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the management of a patient with metastatic squamous NSCLC. Listen to the episode to learn how the guests would approach this case. Guest: Dr. Pilar Garrido is an Associate Professor of Medical Oncology at Universidad de Alcalá in Madrid, Spain, and the Head of the Thoracic Tumours Section at the University Hospital Ramón y Cajal X: @Piuchagarrido Guest: Dr. Jared Weiss is a Professor of Medicine and Section Chief of Thoracic and Head & Neck Oncology at the University of North Carolina, Chapel Hill, N.C. @DrJaredWeiss

In this episode of Lung Cancer Considered, Dr. Aakash Desai moderates a discussion in Hindi on management of non-small cell lung cancer and small cell lung cancer in the Indian context. The group discusses advances in immunotherapy in resectable NSCLC and other new treatments on the horizon. Host: Dr. Aakash Desai is an Assistant Professor of Medicine at the O'Neal Comprehensive Cancer Center, University of Alabama in Birmingham, Alabama. He is the Co-Chair, Lung Cancer Working Group, and Associate Director, Phase 1 and Precision Oncology Program. Guest: Dr. Navneet Singh is a Professor, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education & Research (PGIMER) in Chandigarh, India. Guest: Dr. Sewanti Limaye is the Director of Medical & Precision Oncology and Director of Clinical and Translational Oncology Research at the Sir HN Reliance Foundation Hospital and Research Centre in Mumbai, India. She is the Co-Chair of the Asia Pacific Coalition Against Lung Cancer.

Description: As the incidence of lung cancer in those under age 35 increases, oncologists are finding that pregnancy is a central issue for many young women who are coping with lung cancer. In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guests discuss some of the critical issues facing women with lung cancer who are pregnant, or attempting to start a family. Guest: Dr. Ross Camidge is a Thoracic Medical Oncologist and the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado. Guest: Dr. Martina Imbimbo is a Thoracic Medical Oncologist at the IOSI Oncology Institute of Southern Switzerland where she specializes in immunooncology and targeted therapy.

The Power of Movement: Exercise and Lung Cancer-- a Conversation with Experts Description: In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion about the role exercise plays in complementing cancer treatment and how clinicians can work with patients to add regular exercise to their daily regimen. Guest: Dr. Morten Quist is an associate professor at Copenhagen University and a Physiotherapist Clinician-Researcher with 20 years expertise prescribing exercise for patients with cancer at the University Hospital of Copenhagen (Rigshospitalet). He is the Co-founder of the “Body and Cancer” and Founder of the EXHALE programs. Guest: Nancy Campbell is a Clinical Exercise Physiologist in the Zakim Center at Dana-Farber Cancer Institute, and she is a Certified ACE Personal Trainer, and has earned the American College of Sports Medicine Cancer Exercise Trainer Certification. Guest: Dr. Paulo Bergerot is a Medical Oncologist at Oncoclinicas in Brazil, where he specializes in GU malignancies, and focuses on research in the area of exercise and cancer. He has created a remote exercise program for cancer survivors.

Title: IASLC Hot Topic Meeting on Tolerance and Resistance to Targeted Therapy in NSCLC (recorded on 10/21) Description: In this episode of Lung Cancer Considered, host Dr. Stephen Liu previews the upcoming IASLC Hot Topic Meeting on Tolerance and Resistance to Targeted Therapy in NSCLC. To discuss this exciting new meeting and this topic, he is joined by the four co-chairs of the meeting. To learn more about the meeting, visit https://www.httr2024-iaslc.org/. Guest: Dr. Alice Berger is an Associate Professor in the Human Biology Division and the Herbold Computational Biology Program at the Fred Hutchinson Cancer Center at the University of Washington in Seattle, Wash. X: @aliceb_phd Guest: Dr. Kenichi Suda, Associate Professor in the Division of Thoracic Surgery at Kindai University School of Medicine in Osaka, Japan. X: NA Guest: Dr. Montse Sanchez-Cespedes is the Group Leader at the Josep Carreras Research Institute, in Badalona, Spain X: @CespedesMontse Guest: Dr. William Lockwood, Senior Scientist in Integrative Oncology at the BC Cancer Research Institute and Associate Professor in Pathology & Laboratory Medicine at the University of British Columbia in Vancouver, Canada X: @WWL_18

As part of the IASLC's ongoing series of podcasts in world languages, this episode brings together two leading lung cancer experts who discuss training and education in medical oncology and lung cancer in Arabic. Host: Dr. Nagla Abdel Karim Thoracic Medical Oncologist, Director of Developmental Therapeutics at Inova Schar Cancer Institute Professor of Medicine at the University of Virginia School of Medicine Guest: Dr. Rami Manochakian, FASCO Associate Professor of Medicine and Consultant, Thoracic Oncology Mayo Clinic Florida

In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a discussion about the management of relapsed SCLC, which remains a very challenging cancer to treat, despite recent progress. Guest: Dr. Malinda Itchins is a Medical Oncologist at Royal North Shore Hospital, Visiting Medical Officer for Thoracic Cancers at Chris O'Brien Lifehouse, and Faculty at the University of Sydney. She is the Board Director and Lung Cancer Chair for the Clinical Oncology Society of Australia (COSA) and the Scientific Committee Advanced NSCLC Group Co-Chair for the Thoracic Oncology Group of Australasia (TOGA). Guest: Dr. Jacob Sands is an Assistant Professor at Harvard Medical School and Thoracic Medical Oncologist at the Lowe Center for Thoracic Oncology at the Dana Farber Cancer Institute, where he leads the Clinical Research Program in SCLC. Jacob is also Co-founder and President of the Rescue Lung Society, a 501(c)3 society focused on advancing lung cancer screening.

Lung Cancer Considered--Managing ADC Toxicities by IASLC

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC's 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Nagla Abdel Karim moderates a discussion in Arabic about highlights from the conference with Dr. Fawzi Abu Rous, Dr. Raid Aljumaily, Dr. Abdulaziz AlJassim, and Dr. Ashraf Mohamed. Host: Dr. Nagla Abdel Karim Thoracic Medical Oncologist, Director of Developmental Therapeutics at Inova Schar Cancer Institute Professor of Medicine at the University of Virginia School of Medicine Guests: Dr. Fawzi Abu Rous Thoracic Medical Oncologist Henry Ford Health, Detroit, MI Dr. Raid Aljumaily Associate Professor of Medicine University of Oklahoma Dr. Abdulaziz AlJassim Senior Specialist in Thoracic Medical Oncology and Internal Medicine. Kuwait Cancer Control Center, Kuwait Dr. Ashraf Mohamed Director of Surgery Business Development Siemens Healthineers

Host Dr. Narjust Florez previews the 2024 Latin America Lung Cancer Meeting with co-chairs Dr. Lucia Viola, Dr. Andres Feliple Cardona and Dr. Stella Martinez. LALCA is a dynamic meeting with a long tradition that features the most up-to-date research, diverse topics of interest, and educational sessions with leading experts. Guest: Dr. Lucia Viola Interventional Pulmonologist- Head of Thoracic Oncology Service. She is a member of the Fundación Neumológica Colombiana - Fundación CTICGuest: Dr. Andrés Felipe Cardona is the Director of Research, Science and Education of the Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC) located in Bogotá, Colombia. Guest: Dr. Stella Martinez is an Associate Professor of thoracic Surgery and Director of the Specialization Program in Thoracic Surgery at El Bosque University in Bogotá, Colombia.

This episode of Lung Cancer Considered covers the recently completed 2024 ESMO Congress in Barcelona. Host Dr. Stephen Liu discussed the important research presented at the meeting with Dr. Marina Garassino and Dr. Federico Cappuzzo.

In a special episode of Lung Cancer Considered, host Dr. Stephen Liu discuss the recent FDA approval of pembrolizumab plus platinum and pemetrexed for mesothelioma, based on the phase III KEYNOTE 483 study. Guest: Dr. Ibiayi Dagogo-Jack is a thoracic oncologist from Massachusetts General Hospital and Assistant Professor at Harvard Medical School Guest: Dr. Quincy Chu is a thoracic oncologist at the University of Alberta Cross Cancer Institute's New Drug Development Program and CCTG Investigational New Drug Committee Chair